Elixir Medical’s coronary implant, DynamX bioadaptor, has been proven to significantly reduce the risk of device-related cardiac events compared with current-generation drug-eluting stents in a ...

Dramatically thinner scaffold combines excellent deliverability and conformability with DESolve’s market-leading clinical benefits SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a ...

Results Set a High Standard in Sustained Long Term Clinical Outcomes Sunnyvale, CA— Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced ...

MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced it has appointed Alaeddin Ahram as Executive Vice President, ...

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX ® compared to DES— —Significantly lower ...

MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced it has appointed Alexey (Alex) Nepogodiev as Executive Vice President ...

Elixir Medical Corp., reported positive 12-month results for its Dynamx Coronary Bioadaptor System, with no target vessel revascularization (TVR) or stent thrombosis and adaptive remodeling of the ...

Receipt of EU MDR CE mark may not be a magic potion, but Elixir Medical Corp. is certainly feeling a boost from the regulatory nod for its mechanical Lithix hertz contact intravascular lithotripsy ...

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...

Elixir Medical's DynamX bioadaptor has been shown to diminish target lesion failure (TLF) by 48% in a landmark clinical trial. Image credit: Jo Panuwat D via Shutterstock.com. Elixir Medical’s ...